文献速递基础与转化研究新药、器械与细胞基因治疗研发

miR-200c-EpCAM轴异位激活增强过继细胞治疗模型的抗肿瘤T细胞应答

Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy.
PubMed 文献 · Sci Transl Med · 2021-09-15

该研究在多种小鼠模型中发现,过表达microRNA-200c(miR-200c)可显著增强CD8+细胞毒性T淋巴细胞(CTL)在过继T细胞治疗(ACT)中的抗肿瘤活性。miR-200c通过抑制转录因子Zeb1诱导上皮细胞特征基因,其中Epcam过表达足以增强针对实体瘤和血液瘤的治疗性T细胞应答。

要点

  • miR-200c过表达减少CTL植入过程中的凋亡并增强体内持久性。
  • miR-200c通过抑制Zeb1上调TCF1和TNF,诱导上皮细胞特征基因。
  • Epcam过表达足以增强针对实体瘤和血液瘤的T细胞应答。

核心结论

  • miR-200c-EpCAM轴是改善过继T细胞治疗的潜在途径。
  • 特定基因扰动可产生表型独特且具有治疗优势的T细胞。

研究设计与样本

  • 研究在多种小鼠模型中开展过继T细胞治疗(ACT)实验。
  • 采用miR-200c转导的CD8+细胞毒性T淋巴细胞(CTL)进行过继转移。

主要发现

  • miR-200c过表达显著增强CD8+CTL在ACT中的抗肿瘤活性。
  • miR-200c转导的CTL在植入过程中凋亡减少且体内持久性增强。
  • 伴随转录调节因子TCF1和炎性细胞因子TNF的上调。
  • miR-200c通过抑制转录因子Zeb1诱导上皮细胞特征基因。
  • Epcam过表达足以增强针对实体瘤和血液瘤的治疗性T细胞应答。

临床怎么用

  • miR-200c-EpCAM轴可作为改进ACT的基因扰动靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adoptive T cell therapy (ACT) is a promising strategy for treating cancer, but it often fails because of cell intrinsic regulatory programs that limit the degree or duration of T cell function. In this study, we found that ectopic expression of microRNA-200c (miR-200c) markedly enhanced the antitumor activity of CD8+ cytotoxic T lymphocytes (CTLs) during ACT in multiple mouse models. CTLs transduced with miR-200c exhibited reduced apoptosis during engraftment and enhanced in vivo persistence, accompanied by up-regulation of the transcriptional regulator T cell factor 1 (TCF1) and the inflammatory cytokine tumor necrosis factor (TNF). miR-200c elicited these changes by suppressing the transcription factor Zeb1 and thereby inducing genes characteristic of epithelial cells. Overexpression of one of these genes, Epcam, was sufficient to augment therapeutic T cell responses against both solid and liquid tumors. These results identify the miR-200c–EpCAM axis as an avenue for improving ACT and demonstrate that select genetic perturbations can produce phenotypically distinct T cells with advantageous therapeutic properties.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Zhang M, Zhao Z, Pritykin Y, et al. Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. Sci Transl Med. 2021. PMID: 34524864. doi:10.1126/scitranslmed.abg4328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。